Generating a precision endoxifen prediction algorithm to advance personalized tamoxifen treatment in patients with breast cancer
T Helland, S Alsomairy, C Lin, H Søiland… - Journal of Personalized …, 2021 - mdpi.com
Tamoxifen is an endocrine treatment for hormone receptor positive breast cancer. The
effectiveness of tamoxifen may be compromised in patients with metabolic resistance, who …
effectiveness of tamoxifen may be compromised in patients with metabolic resistance, who …
Personalizing tamoxifen therapy in adjuvant therapy: a brief summary of the ongoing discussion
A Sanchez-Spitman, HJ Guchelaar - Expert Review of Clinical …, 2023 - Taylor & Francis
Breast cancer still remains the most common form of cancer diagnosed among women [1],
and it represents 15% of all cancer deaths in female patients [2]. Around 60% of the new …
and it represents 15% of all cancer deaths in female patients [2]. Around 60% of the new …
Developing a nationwide infrastructure for therapeutic drug monitoring of targeted oral anticancer drugs: the ON-TARGET study protocol
AM Mc Laughlin, E Schmulenson, O Teplytska… - Cancers, 2021 - mdpi.com
Simple Summary Relationships between drug concentrations in blood and efficacy and/or
toxicity have been reported for up to 80% of oral anticancer drugs (OADs). Most OADs …
toxicity have been reported for up to 80% of oral anticancer drugs (OADs). Most OADs …
Computational treatment simulations to assess the need for personalized tamoxifen dosing in breast cancer patients of different biogeographical groups
A Mueller-Schoell, R Michelet, L Klopp-Schulze… - Cancers, 2021 - mdpi.com
Simple Summary Tamoxifen is a drug often used to treat the most common type of breast
cancer. Its metabolite endoxifen is formed by the liver enzyme CYP2D6, whose activity is …
cancer. Its metabolite endoxifen is formed by the liver enzyme CYP2D6, whose activity is …
[PDF][PDF] Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol. Cancers 2021, 13 …
AM Mc Laughlin, E Schmulenson, O Teplytska… - 2021 - researchgate.net
Exposure-efficacy and/or exposure-toxicity relationships have been identified for up to 80%
of oral anticancer drugs (OADs). Usually, OADs are administered at fixed doses despite their …
of oral anticancer drugs (OADs). Usually, OADs are administered at fixed doses despite their …